PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy of Prostate Cancer

Abstract Molecular changes in prostate cancer lead to increased expression of prostate-specific membrane antigen (PSMA), which is a suitable target for imaging and therapy using radiopharmaceuticals. Data on the most effective clinically significant PSMA radiopharmaceuticals for the diagnosis and treatment of prostate cancer are summarized. The advantages and disadvantages of ligands based on monoclonal antibodies and their fragments as well as small molecular PSMA inhibitors are discussed.

Authors
Ivanov S.A. 1 , Kaprin A.D. 1 , Tishchenko V.K. , Petriev V.M. , Vlasova O.P. , Krylov V.V. , Shegai P.V.
Journal
Physics of Atomic Nuclei
Number of issue
9
Pages
1608-1612
Status
Published
DOI
10.1134/S106377882209037X
Volume
85
Year
2022
Organizations
  • 1 Peoples Friendship University of Russia
Keywords
prostate-specific membrane antigen (PSMA); prostate cancer; monoclonal antibodies; small molecule PSMA inhibitors
Date of creation
21.04.2023
Date of change
21.04.2023
Short link
https://repository.rudn.ru/en/records/article/record/93449/
Share

Other records